Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine: COMMENT from Gruel et al.: RESPONSE from Kahn et al

Affiliations

Comment

Fredrik Kahn et al. J Thromb Haemost. 2021 Oct.

. 2021 Oct;19(10):2633.

doi: 10.1111/jth.15467. Epub 2021 Aug 5.

¹ Division of Infection Medicine, Clinical Sciences, Lund University, Lund, Sweden.

No abstract available

Keywords: IdeS; drug-related side effects and adverse reactions; platelet factor 4; thrombocytopenia; vaccine.

Comment on

Reply to the letter entitled "Suggested treatment of serious complications to Covid-19 vaccination with IdeS, a bacterial antibody-cleaving enzyme".
Gruel Y, Vayne C, Rollin J, Pouplard C. Gruel Y, et al. J Thromb Haemost. 2021 Oct;19(10):2632. doi: 10.1111/jth.15465. Epub 2021 Jul 30. J Thromb Haemost. 2021. PMID: 34331369 Free PMC article. No abstract available.

1. Kahn F., Shannon O., Björck L. Suggested treatment of serious complications to COVID‐19 vaccination with IdeS, a bacterial antibody‐cleaving enzyme. J Thromb Haemost. 2021 doi: 10.1111/jth.15433. - DOI - PMC - PubMed
1. Kizlik‐Masson C., Deveuve Q., Zhou Y., et al. Cleavage of anti‐PF4/heparin IgG by a bacterial protease and potential benefit in heparin‐induced thrombocytopenia. Blood. 2019;133:2427–2435. - PubMed
1. von Pawel‐Rammingen U., Johansson B.P., Björck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002;21:1607–1615. - PMC - PubMed
1. Johansson B.P., Shannon O., Björck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One. 2008;3 - PMC - PubMed